Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2013, Article ID 541871, 11 pages
http://dx.doi.org/10.1155/2013/541871
Research Article

Effects of PPARγ Agonist Pioglitazone on Redox-Sensitive Cellular Signaling in Young Spontaneously Hypertensive Rats

1Institute of Normal and Pathological Physiology, SAS, Sienkiewiczova 1, 813 71 Bratislava, Slovakia
2Institute for Heart Research, SAS, Dubravska cesta 9, 840 05 Bratislava, Slovakia
3Institute of Experimental Endocrinology, SAS, Vlarska 3, 833 06 Bratislava, Slovakia
4Center for Translational Research in Biomedical Science, Kaohsiung Chang Gang Memorial Hospital, 123 Ta Pei Road, Kaohsiung 83301, Taiwan

Received 26 July 2013; Revised 17 October 2013; Accepted 6 November 2013

Academic Editor: Nanping Wang

Copyright © 2013 Ima Dovinová et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. E. Lob, P. J. Marvar, T. J. Guzik et al., “Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system,” Hypertension, vol. 55, no. 2, pp. 277–283, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Majzunova, I. Dovinova, M. Barancik, and J. Y. Chan, “Redox signaling in pathophysiology of hypertension,” Journal of Biomedical Science, vol. 20, no. 1, p. 69, 2013. View at Google Scholar
  3. S. Polvani, M. Tarocchi, and A. Galli, “PPAR and oxidative stress: Con(β) catenating NRF2 and FOXO,” PPAR Research, vol. 2012, Article ID 641087, 15 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. K. L. Houseknecht, B. M. Cole, and P. J. Steele, “Peroxisome proliferator-activated receptor gamma (PPARγ) and its ligands: a review,” Domestic Animal Endocrinology, vol. 22, no. 1, pp. 1–23, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Kleinhenz, D. J. Kleinhenz, S. You et al., “Disruption of endothelial peroxisome proliferator-activated receptor-γ reduces vascular nitric oxide production,” American Journal of Physiology, vol. 297, no. 5, pp. H1647–H1654, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. H. H. Chan, K. L. H. Wu, P. S. S. Kung, and J. Y. H. Chan, “Oral intake of rosiglitazone promotes a central antihypertensive effect via upregulation of peroxisome proliferator-activated receptor-γ and alleviation of oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats,” Hypertension, vol. 55, no. 6, pp. 1444–1453, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Li, H. Zhang, W. Wang et al., “Vascular insulin resistance in prehypertensive rats: role of PI3-kinase/Akt/eNOS signaling,” European Journal of Pharmacology, vol. 628, no. 1–3, pp. 140–147, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Gao, N. Ning, G. Hao, and X. Niu, “Pioglitazone attenuates vascular fibrosis in spontaneously hypertensive rats,” PPAR Research, vol. 2012, Article ID 856426, 7 pages, 2012. View at Publisher · View at Google Scholar
  9. G. Ding, M. Fu, Q. Qin et al., “Cardiac peroxisome proliferator-activated receptor γ is essential in protecting cardiomyocytes from oxidative damage,” Cardiovascular Research, vol. 76, no. 2, pp. 269–279, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Okuno, M. Matsuda, Y. Miyata et al., “Human catalase gene is regulated by peroxisome proliferator activated receptor-gamma through a response element distinct from that of mouse,” Endocrine Journal, vol. 57, no. 4, pp. 303–309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. G. D. Girnun, F. E. Domann, S. A. Moore, and M. E. C. Robbins, “Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter,” Molecular Endocrinology, vol. 16, no. 12, pp. 2793–2801, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Zhao, A. Patzer, T. Herdegen, P. Gohlke, and J. Culman, “Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats,” The FASEB Journal, vol. 20, no. 8, pp. 1162–1175, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Collino, M. Aragno, R. Mastrocola et al., “Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion,” European Journal of Pharmacology, vol. 530, no. 1-2, pp. 70–80, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Birnbaum, B. Long, J. Qian, J. R. Perez-Polo, and Y. Ye, “Pioglitazone limits myocardial infarct size, activates Akt, and upregulates cPLA2 and COX-2 in a PPAR-γ-independent manner,” Basic Research in Cardiology, vol. 106, no. 3, pp. 431–446, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Yasuda, H. Kobayashi, M. Iwasa et al., “Antidiabetic drug pioglitazone protects the heart via activation of PPAR-γ receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction,” American Journal of Physiology, vol. 296, no. 5, pp. H1558–H1565, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Goetze, F. Eilers, A. Bungenstock et al., “PPAR activators inhibit endothelial cell migration by targeting Akt,” Biochemical and Biophysical Research Communications, vol. 293, no. 5, pp. 1431–1437, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Xiao, T. Yuan, W. Yao, and K. Liao, “3T3-L1 adipocyte apoptosis induced by thiazolidinediones is peroxisome proliferator-activated receptor-γ-dependent and mediated by the caspase-3-dependent apoptotic pathway,” FEBS Journal, vol. 277, no. 3, pp. 687–696, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Fang, D. Hawke, Y. Zheng et al., “Phosphorylation of β-catenin by AKT promotes β-catenin transcriptional activity,” Journal of Biological Chemistry, vol. 282, no. 15, pp. 11221–11229, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Hoogeboom and B. M. T. Burgering, “Should I stay or should I go: β-catenin decides under stress,” Biochimica et Biophysica Acta, vol. 1796, no. 2, pp. 63–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Kopincová, A. Púzserová, and I. Bernátová, “Chronic low-dose L-NAME treatment effect on cardiovascular system of borderline hypertensive rats: feedback regulation?” Neuroendocrinology Letters, vol. 29, no. 5, pp. 784–789, 2008. View at Google Scholar · View at Scopus
  21. M. Shargorodsky, K. Michaelova, M. Boaz, D. Gavish, and R. Zimlichman, “Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with type 2 diabetes mellitus: a 2-year follow-up study,” Diabetic Medicine, vol. 24, no. 11, pp. 1254–1260, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Pravenec, V. Zídek, V. Landa et al., “Age-related autocrine diabetogenic effects of transgenic resistin in spontaneously hypertensive rats: gene expression profile analysis,” Physiological Genomics, vol. 43, no. 7, pp. 372–379, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Collino, M. Aragno, S. Castiglia et al., “Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation,” British Journal of Pharmacology, vol. 160, no. 8, pp. 1892–1902, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Barbieri, C. Di Filippo, A. Esposito et al., “Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ -knockout (CM-PGKO) mice,” PLoS ONE, vol. 7, no. 4, Article ID e35999, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Ye, Y. Lin, S. Atar et al., “Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions,” American Journal of Physiology, vol. 291, no. 3, pp. H1158–H1169, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. D. H. Kim, S. C. Woods, and R. J. Seeley, “Hypothalamic Akt/PKB signaling in regulation of food intake,” Fronteer in Bioscience, vol. 4, pp. 953–966, 2012. View at Google Scholar
  27. H. Kawabata and K. Ishikawa, “Cardioprotection with pioglitazone is abolished by nitric oxide synthase inhibitor in ischemic rabbit hearts—comparison of the effects of pioglitazone and metformin,” Diabetes/Metabolism Research and Reviews, vol. 19, no. 4, pp. 299–305, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Nishio, M. Shigemitsu, Y. Kodama et al., “The effect of pioglitazone on nitric oxide synthase in patients with type 2 diabetes mellitus,” Journal of the cardiometabolic syndrome, vol. 3, no. 4, pp. 200–204, 2008. View at Google Scholar · View at Scopus
  29. A. Kondrashov, S. Vranková, I. Dovinová et al., “The effects of new Alibernet red wine extract on nitric oxide and reactive oxygen species production in spontaneously hypertensive rats,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 806285, 8 pages, 2012. View at Publisher · View at Google Scholar
  30. A. H. Dorafshar, K. Moodley, M. Khoe, C. Lyon, and M. Bryer-Ash, “Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat,” Diabetes and Vascular Disease Research, vol. 7, no. 1, pp. 20–27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Gumieniczek, Ł. Komsta, and M. R. Chehab, “Effects of two oral antidiabetics, pioglitazone and repaglinide, on aconitase inactivation, inflammation and oxidative/nitrosative stress in tissues under alloxan-induced hyperglycemia,” European Journal of Pharmacology, vol. 659, no. 1, pp. 89–93, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. G. D. Girnun, W. M. Smith, S. Drori et al., “APC-dependent suppression of colon carcinogenesis by PPARγ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 21, pp. 13771–13776, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. T.-P. Alastalo, M. Li, V. De Jesus Perez et al., “Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival,” The Journal of Clinical Investigation, vol. 121, no. 9, pp. 3735–3746, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Lu and D. A. Carson, “Repression of β-catenin signaling by PPARγ ligands,” European Journal of Pharmacology, vol. 636, no. 1–3, pp. 198–202, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Sharma, A. Pradeep, L. Wong, A. Rana, and B. Rana, “Peroxisome proliferator-activated receptor γ activation can regulate β-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway,” Journal of Biological Chemistry, vol. 279, no. 34, pp. 35583–35594, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Kanda, M. Matsuda, K. Tawaramoto et al., “Effects of sulfonylurea drugs on adiponectin production from 3T3-L1 adipocytes: implication of different mechanism from pioglitazone,” Diabetes Research and Clinical Practice, vol. 81, no. 1, pp. 13–18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. J. MacKellar, S. W. Cushman, and V. Periwal, “Differential effects of thiazolidinediones on adipocyte growth and recruitment in Zucker fatty rats,” PLoS ONE, vol. 4, no. 12, Article ID e8196, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. J. G. Kang, C.-Y. Park, S.-H. Ihm et al., “Mechanisms of adipose tissue redistribution with rosiglitazone treatment in various adipose depots,” Metabolism, vol. 59, no. 1, pp. 46–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Harte, P. McTernan, R. Chetty et al., “Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone,” Circulation, vol. 111, no. 15, pp. 1954–1961, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Saiki, M. Ohira, K. Endo et al., “Pioglitazone decreases plasma angiotensin II concentration in type 2 diabetes,” Journal of Atherosclerosis and Thrombosis, vol. 17, no. 6, pp. 651–657, 2010. View at Google Scholar · View at Scopus